Dr David Peter Ellent, MD | |
22751 Professional Dr Ste 140, Kingwood, TX 77339-6024 | |
(281) 975-1000 | |
(281) 783-2505 |
Full Name | Dr David Peter Ellent |
---|---|
Gender | Male |
Speciality | Hematology/oncology |
Experience | 24 Years |
Location | 22751 Professional Dr Ste 140, Kingwood, Texas |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1427081710 | NPI | - | NPPES |
111815002 | Medicaid | TX |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RH0003X | Internal Medicine - Hematology & Oncology | L7366 (Texas) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Kingwood Medical Center | Kingwood, TX | Hospital |
Memorial Hermann Northeast Hospital | Humble, TX | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
David P Ellent Pllc | 7012290885 | 36 |
News Archive
Individuals who have attempted suicide and also have a history of self-harm should be thoroughly assessed for psychotic symptoms in order to prevent delayed treatment and the risk for repeated suicide attempts, say researchers.
Omeros Corporation today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration for prevention of complement-mediated thrombotic microangiopathies.
CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.
The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tumours were reported today at the ESMO 2016 Congress in Copenhagen.
› Verified 6 days ago
Entity Name | David P Ellent Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1245777440 PECOS PAC ID: 7012290885 Enrollment ID: O20170202000805 |
News Archive
Individuals who have attempted suicide and also have a history of self-harm should be thoroughly assessed for psychotic symptoms in order to prevent delayed treatment and the risk for repeated suicide attempts, say researchers.
Omeros Corporation today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration for prevention of complement-mediated thrombotic microangiopathies.
CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.
The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tumours were reported today at the ESMO 2016 Congress in Copenhagen.
› Verified 6 days ago
Entity Name | Creekside Premier Medical Group Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1487217006 PECOS PAC ID: 6406203298 Enrollment ID: O20231116000915 |
News Archive
Individuals who have attempted suicide and also have a history of self-harm should be thoroughly assessed for psychotic symptoms in order to prevent delayed treatment and the risk for repeated suicide attempts, say researchers.
Omeros Corporation today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration for prevention of complement-mediated thrombotic microangiopathies.
CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.
The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tumours were reported today at the ESMO 2016 Congress in Copenhagen.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Dr David Peter Ellent, MD 2255 E Mossy Oaks Rd Ste 500, Spring, TX 77389-1813 Ph: (281) 440-5300 | Dr David Peter Ellent, MD 22751 Professional Dr Ste 140, Kingwood, TX 77339-6024 Ph: (281) 975-1000 |
News Archive
Individuals who have attempted suicide and also have a history of self-harm should be thoroughly assessed for psychotic symptoms in order to prevent delayed treatment and the risk for repeated suicide attempts, say researchers.
Omeros Corporation today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration for prevention of complement-mediated thrombotic microangiopathies.
CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.
The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tumours were reported today at the ESMO 2016 Congress in Copenhagen.
› Verified 6 days ago
Liza Jemison, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1330 Kingwood Dr, Suite 200, Kingwood, TX 77339 Phone: 281-348-7301 Fax: 281-348-2186 | |
Dr. Mohamed Wael J Khirfan, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 24044 Highway 59 N, Kingwood, TX 77339 Phone: 281-674-7812 Fax: 281-310-6602 | |
Dr. Sivatej Sarva, M.B.B.S Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 451 Kingwood Medical Dr Ste 100, Kingwood, TX 77339 Phone: 281-318-2043 Fax: 281-536-6306 | |
Branden Carl Wilson, DO Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 22999 Highway 59 N Ste 105, Kingwood, TX 77339 Phone: 281-348-8934 | |
Dr. Syed Arman Raza, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2627 Chestnut Ridge Dr, Suite 100, Kingwood, TX 77339 Phone: 281-358-1950 Fax: 281-358-3102 | |
Dr. Mary K Crow, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 22710 Professional Dr, Kingwood, TX 77339 Phone: 281-298-8444 Fax: 281-298-7720 | |
Mr. Alexander Tiu, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 22999 Highway 59 N, # 214, Kingwood, TX 77339 Phone: 281-359-5010 Fax: 281-359-5131 |